Tempus AI (TEM) Diagnostics CEO sells 1,580 shares for RSU tax withholding
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI (TEM), sold 1,580 shares of Class A common stock for a weighted average price of $44.07 per share. This transaction was not a discretionary sale but a mandated "sell to cover" to fulfill statutory tax withholding obligations related to the vesting of restricted stock units. Following this sale, Schoenherr directly holds 107,029 shares of Tempus AI.
Tempus AI (TEM) executive logs 13,550-share tax sell-to-cover transaction
Tempus AI (TEM) executive Fukushima Ryan sold 13,550 shares of Class A Common Stock at a weighted average price of $44.07 per share. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations from restricted stock unit vesting, not a discretionary sale. Following the transaction, Ryan directly holds 603,558 shares and indirectly holds 211,047 shares through his spouse.
Tempus AI (TEM) CAO executes mandatory sell-to-cover for RSU taxes
Tempus AI's Chief Accounting Officer, Ryan M. Bartolucci, sold 4,116 shares of Class A Common Stock on May 19, 2026, at a weighted average price of $44.07 per share. This sale was a mandatory "sell to cover" transaction to satisfy tax withholding obligations on vested restricted stock units, not a discretionary sale. Following this transaction, Bartolucci directly holds 74,041 shares of Tempus AI Class A Common Stock.
Tempus AI (TEM) legal chief’s non-discretionary tax sell-to-cover trade
Tempus AI's EVP and Chief Legal Officer, Andrew Polovin, sold 8,703 shares of Class A Common Stock at a weighted average price of $44.07 per share. This transaction was a non-discretionary "sell to cover" sale to fund statutory tax withholding obligations related to vested restricted stock units, as mandated by the company’s equity plan. Post-sale, Polovin directly holds 128,215 shares of Tempus AI Class A Common Stock.
Tempus AI (TEM) CEO Lefkofsky sells 22,335 shares to cover RSU taxes
Tempus AI (TEM) CEO Eric P. Lefkofsky sold 22,335 Class A shares at a weighted average price of $44.07 per share on May 19, 2026. This transaction was a "sell to cover" to meet statutory tax withholding obligations related to the vesting of restricted stock units (RSUs) and was not a discretionary sale. Following the sale, Lefkofsky directly holds 2,230,721 Class A shares and maintains significant indirect holdings through various entities.
Tempus AI (TEM) CFO’s mandated share sale covers RSU tax obligations
Tempus AI's Chief Financial Officer, James William Rogers, sold 10,853 shares of Class A Common Stock on May 19, 2026, at a weighted average price of $44.07 per share. This mandatory sale was executed to cover statutory tax withholding obligations stemming from the vesting of restricted stock units (RSUs) and was not a discretionary decision by the executive. Following the transaction, Rogers directly holds 126,395 shares of Tempus AI Class A Common Stock.
Cash per share of Tempus AI, Inc. Class A – HAM:F3M
This article provides financial information for Tempus AI, Inc. Class A (HAM:F3M), specifically focusing on its cash per share data. It includes a basic overview of the company's financial performance by period, value, and change, as presented on TradingView. The content also lists various data providers and copyright notices.
TEM (NASDAQ: TEM) director reports sale of 2,902 shares for $171K
A director at Tempus AI, Inc. (NASDAQ: TEM) has reported the sale of 2,902 Class A shares, valued at $171,371.31, on February 19, 2026, through a Form 144 SEC filing. The filing also details several Restricted Stock Unit (RSU) grants with various acquisition dates and notes a company figure of 174,520,978 shares as of May 19, 2026. While the sale is documented, the specific source of the shares (i.e., from which RSU grant) is not explicitly stated in the excerpt provided.
TEM (NASDAQ: TEM) notice: insider plans to sell RSU-derived Class A shares
Tempus AI (NASDAQ: TEM) has filed a Form 144 notice indicating proposed sales of Class A Common Stock derived from Restricted Stock Units. The filing lists 7 shares from RSUs dated October 23, 2025, and 1,573 shares from RSUs dated April 22, 2026, with an associated date of May 19, 2026. This is a routine notice of proposed sales under resale rules, not a confirmation of completed transactions, and the shares are to be sold through Morgan Stanley Smith Barney LLC.
[144] Tempus AI, Inc. SEC Filing
Tempus AI, Inc. (TEM) has filed a Form 144 notice with the SEC, reporting proposed resale and prior 10b5-1 sales activity of Class A Common Stock by an insider, Erik Phelps. The filing details recent sales on February 19, 2026, totaling 9,464 shares for over $562,000, and several Restricted Stock Unit issuances to Phelps between 2023 and 2026. This SEC filing serves as a procedural notification for intended or recent resales under applicable rules.
TEM (NASDAQ: TEM) Rule 144 lists RSUs and two 10b5-1 sales by Andrew Polovin
Tempus AI (TEM) has filed a Rule 144 notice detailing Restricted Stock Units granted between 2022 and 2026. The filing also reports two recent 10b5-1 sales of Class A Common Stock by Andrew Polovin on February 19 and 20, 2026, totaling over 19,000 shares for more than $1.1 million. These sales were pre-arranged under a 10b5-1 trading plan.
Eric Lefkofsky sells TEM (NASDAQ: TEM) Class A shares reported in Form 144
Eric Lefkofsky and affiliated entities GMD and BMD reported sales of Tempus AI, Inc. (NASDAQ: TEM) Class A Common Stock through a Form 144 filing. The filing details multiple dispositions from February 19, 2026, to April 28, 2026, by Eric Lefkofsky, Blue Media, LLC, and Gray Media, LLC, along with related proceeds. The sales include a total of 13,587 shares by Eric Lefkofsky and substantial sales by the affiliated media companies, with the filing also referencing previously granted Restricted Stock Units.
Long term debt to total assets ratio of Tempus AI, Inc. Class A – HAM:F3M
This article provides financial data for Tempus AI, Inc. Class A, specifically its long-term debt to total assets ratio. The information is presented in the context of the Hamburg Stock Exchange under the ticker F3M, with data provided by ICE Data Services and FactSet.
Tempus AI (NASDAQ: TEM) prices $460M 0% 2032 convertible notes and repays debt
Tempus AI (NASDAQ: TEM) successfully completed a private offering of $460 million in 0.00% Convertible Senior Notes due 2032. The company used approximately $307.7 million of the net proceeds to repay outstanding loans under its senior secured credit facilities and allocated $31.2 million for capped call transactions. The remaining funds are intended for general corporate purposes, including potential acquisitions and strategic investments.
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes
Tempus AI, Inc. (NASDAQ: TEM) announced the pricing of an upsized offering of $400.0 million in 0.00% Convertible Senior Notes due 2032 in a private placement. The company intends to use the net proceeds, estimated at approximately $384.1 million, to repay existing senior secured credit facilities, cover capped call transactions, and for general corporate purposes, including potential acquisitions or investments. The Notes will mature in May 2032 and have an initial conversion rate of 14.4388 shares of Class A common stock per $1,000 principal amount.
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD), Tempus AI, Inc. Class A (TEM) and Editas Medicine (EDIT)
This article provides analyst insights on three healthcare companies: Brookdale Senior Living (BKD), Tempus AI, Inc. Class A (TEM), and Editas Medicine (EDIT). Bank of America Securities analysts Joanna Gajuk maintained a Buy rating for Brookdale Senior Living, Michael Ryskin maintained a Hold rating for Tempus AI, and Alec Stranahan maintained a Sell rating for Editas Medicine. The report includes current analyst consensus ratings and price targets for each stock.
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes
Tempus AI, Inc. announced the pricing of an upsized offering of $400.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032. The net proceeds are estimated to be approximately $384.1 million, which Tempus intends to use to repay outstanding loans, cover capped call transactions, and for general corporate purposes. The notes are convertible into cash, Class A common stock, or a combination thereof, and come with specific conversion rates and redemption conditions.
Baillie Gifford holds 4.98% of Tempus AI (NASDAQ: TEM)
Baillie Gifford & Co. has disclosed a 4.98% beneficial ownership stake in Tempus AI (NASDAQ: TEM), amounting to 8,649,356 shares as of March 31, 2026. The investment firm filed an amended Schedule 13G/A, indicating substantial sole voting and dispositive power over these shares. This filing signals Baillie Gifford's passive investment without intent to influence control of the company.
Tempus AI plans $350 million convertible notes offering
Tempus AI announced its intention to offer $350 million in convertible senior notes due 2032 in a private placement. The healthcare AI company, with a $9.61 billion market cap and $1.32 billion in debt, plans to use the proceeds to repay existing loans, fund capped call transactions, and for general corporate purposes. This follows recent financial results showing a 36.1% revenue increase but a wider-than-expected GAAP loss, and a raised price target from TD Cowen.
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
Tempus AI, Inc. (NASDAQ: TEM) announced its intention to offer $350.0 million in Convertible Senior Notes due 2032 through a private placement. The company plans to use the proceeds to repay outstanding loans, reducing interest expenses, and to fund capped call transactions to mitigate potential stock dilution. This move aims to optimize Tempus's capital structure and enhance its financial flexibility.
Tempus AI Lifts 2026 Outlook on Robust Q1 Growth
Tempus AI reported strong financial results for Q1 2026, with revenue increasing by 36.1% and gross profit by 43.1%, leading to a narrowed adjusted EBITDA loss. The company raised its full-year 2026 revenue outlook due to growth in diagnostics and data, expanded collaborations, and new AI-powered tools, despite facing ongoing GAAP net losses and a "Neutral" rating from TipRanks' AI Analyst, Spark, primarily due to losses and cash burn. Tempus AI remains focused on applying AI to precision medicine, especially in oncology.
Tempus AI (TEM) CFO granted 10,000 RSUs as equity award
Tempus AI's Chief Financial Officer, James William Rogers, was granted 10,000 Restricted Stock Units (RSUs) of Class A Common Stock as part of his compensation. This award, which has no cash cost to him, will vest in eight equal quarterly installments beginning November 15, 2026. Following this transaction, Mr. Rogers directly holds 137,248 shares of Tempus AI Class A Common Stock.
Tempus AI (TEM) Diagnostics CEO awarded 13,642 RSUs in equity grant
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI (TEM), was granted 13,642 shares of Class A Common Stock as restricted stock units. This award consists of 3,642 immediately vested RSUs and 10,000 RSUs that will vest in quarterly installments starting November 15, 2026. Following this transaction, Schoenherr directly holds 108,609 shares of Class A Common Stock.
[Form 4] Tempus AI, Inc. Insider Trading Activity
Ryan Fukushima, an executive at Tempus AI, Inc. (TEM), reported the acquisition of 10,000 shares of Class A Common Stock through a compensation-related grant of restricted stock units. These RSUs were granted at $0 per share and will vest in eight equal quarterly installments beginning November 15, 2026. Following this transaction, Fukushima directly holds 779,347 shares and indirectly holds 148,808 shares through his spouse.
Tempus AI Lifts 2026 Outlook on Robust Q1 Growth
Tempus AI reported strong revenue and gross profit growth in Q1 2026, driven by diagnostics and data applications, and narrowed its adjusted EBITDA loss. The company expanded partnerships, launched new AI-powered tools, and raised its full-year 2026 revenue outlook to $1.59–$1.60 billion, projecting positive adjusted EBITDA. Despite ongoing losses and cash burn, these developments underscore Tempus AI's strengthening position in AI-led precision medicine.
Tempus AI Lifts 2026 Outlook on Robust Q1 Growth
Tempus AI reported robust first-quarter 2026 growth with revenues up 36.1% to $348.1 million, driven by strong diagnostics and data performance, and a narrowed adjusted EBITDA loss. The company raised its full-year 2026 revenue outlook to $1.59–$1.60 billion expecting positive adjusted EBITDA, based on surging testing volumes, expanded collaborations, and new AI-powered tools. Despite ongoing GAAP net losses and a "Neutral" rating from TipRanks' AI Analyst due to persistent cash burn, Tempus AI is strengthening its position in AI-led precision medicine.
Tempus AI, Inc. - Class A Common Stock (NQ: TEM
This article provides recent news and financial updates for Tempus AI, Inc. (Nasdaq: TEM). It includes information about stock performance, analyst forecasts, company announcements regarding partnerships, research, and financial results, and discussions of AI's role in healthcare. The news dates range from late August 2024 to November 2024, indicating a compilation of relevant articles.
Tempus AI (TEM) CEO’s entities sell 166,250 shares under Rule 10b5-1 plan
Tempus AI (TEM) CEO Eric Lefkofsky's entities, Blue Media, LLC and Gray Media, LLC, indirectly sold a total of 166,250 shares of Class A Common Stock. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in March 2025, with weighted-average prices around $51 per share. Despite these sales, Lefkofsky maintains significant indirect and direct holdings in the company.
Multiple Class A Common sales reported by holders (NASDAQ: TEM)
A Form 144 filing for Tempus AI, Inc. (NASDAQ: TEM) indicates proposed sales of Class A Common shares by various holders, including Eric Lefkofsky, Blue Media, LLC, and Gray Media, LLC. The sales occurred on February 18, 2026, February 19, 2026, and March 26, 2026, with significant share quantities and corresponding dollar proceeds reported. J.P. Morgan Securities LLC is listed as the broker for these transactions.
Tempus AI faces multiple class action lawsuits
Tempus AI is facing multiple class action lawsuits for allegedly collecting and disclosing genetic testing results from its acquisition of Ambry Genetics without authorization. The lawsuit, consolidated as "Farrier et al v. Tempus AI, Inc.", claims violations of genetic information privacy laws and alleges that Tempus AI profited from selling this genetic data to over 70 companies, despite claims of de-identification. Plaintiffs seek damages and injunctive relief to prevent further unauthorized data sharing.
Mizuho Securities Keeps Their Buy Rating on Tempus AI, Inc. Class A (TEM)
Mizuho Securities analyst Anthony Petrone has maintained a Buy rating on Tempus AI, Inc. Class A (TEM) and set a price target of $100.00. Petrone, a 4-star analyst, covers the Healthcare sector and boasts an average return of 5.4% and a 47.33% success rate. This comes as Tempus AI reported a quarterly revenue of $367.21 million and a GAAP net loss of $54.17 million for the quarter ending December 31.
Tempus AI, Inc. Class A Common Stock (TEM) Live Share Price, Invest From India
This article provides comprehensive financial data for Tempus AI, Inc. Class A Common Stock (TEM), including live share price, performance metrics, historical returns, key fundamentals, and peer comparisons. It also includes quarterly and annual profit & loss statements, cash flow data, and investor sentiment details, catering to Indian investors interested in US stocks. The company's business operations in healthcare technology and strategic collaborations are also highlighted.
tempus AI Inc Class A call volume above normal and directionally bullish
Bullish option flow has been detected in Tempus AI (TEM) Inc Class A, with call volume significantly above normal and implied volatility increasing. The article highlights specific call options that are most active and notes an upcoming earnings date for the company. It also mentions recent analyst activities including upgrades and discussions about Tempus AI's AI data advantage and genomics upside.
Amazon, Snowflake, Tempus AI, Arrive AI And Eos Energy: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks surged following President Donald Trump's announcement of a temporary ceasefire with Iran. This article highlights five stocks—Amazon, Snowflake, Tempus AI, Arrive AI, and Eos Energy—that captured investor attention, detailing their recent performance and key company developments such as Amazon's large investment, Snowflake's AI disruption fears, Tempus AI's collaboration with Gilead, Arrive AI's new patent, and Eos Energy's strong first-quarter revenue projections.
Tempus AI (TEM) plans 2026 virtual meeting, auditor and pay votes
Tempus AI (TEM) has scheduled its 2026 virtual annual meeting for May 21, 2026, where stockholders will vote on electing nine directors, ratifying PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and determining the frequency of future "say-on-pay" votes. The board recommends re-electing all director nominees, ratifying PwC, and holding advisory executive compensation votes every three years. The article also details executive compensation for 2025, including base salaries, bonus awards (paid in RSUs), and long-term equity incentives in the form of performance-based RSUs tied to compound revenue growth and relative Total Shareholder Return.
TEM Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and events related to Tempus AI (TEM) stock, including its collaboration with Gilead Sciences to enhance oncology research and development. It also highlights Cathie Wood's ARK Invest increasing holdings in Tempus AI while divesting other tech stocks. Additionally, the article mentions the positive results from the ALERT trial, which demonstrate how AI-driven notifications improve heart disease treatment.
Tempus AI, Inc. - Class A Common Stock (NQ: TEM)
This article provides a list of recent news headlines, press releases, and research articles related to Tempus AI, Inc. (Nasdaq: TEM). It highlights various developments including new investments, product validations, financial results, and analyst coverage, emphasizing the company's growth and activities in the AI healthcare sector.
Vanguard disaggregates holdings; reports 0 shares of Tempus AI (TEM)
Vanguard has filed an amendment to its Schedule 13G/A, reporting zero beneficial ownership of Tempus AI (TEM) common stock. This change is due to an internal realignment within The Vanguard Group, where certain subsidiaries will now report their beneficial ownership separately. The filing emphasizes that this is an administrative reporting change and not an economic sale or acquisition of Tempus AI shares.
Lefkofsky Eric P, CEO of Tempus AI, sells $7.7 million in stock
Eric P. Lefkofsky, CEO of Tempus AI (NASDAQ:TEM), sold 151,520 shares totaling $7.7 million on March 26, 2026, through entities he manages. Despite the stock's 28% year-to-date decline, Tempus AI reported strong Q4 earnings, surpassing analyst expectations with 83% revenue growth. The company also expanded its collaboration with Merck, leading to mixed analyst price target adjustments.
# Lefkofsky Eric P, CEO of Tempus AI, sells $7.7 million in stock
Eric P. Lefkofsky, CEO of Tempus AI, has sold 151,520 shares of Class A Common Stock for approximately $7.7 million. These sales were executed through entities he manages, following a Rule 10b5-1 trading plan. Despite the stock's 28% year-to-date decline, Tempus AI recently surpassed Q4 earnings expectations with significant revenue growth in its Diagnostics and Data segments and announced an expanded collaboration with Merck.
Lefkofsky Eric P, CEO of Tempus AI, sells $7.7 million in stock
Eric P. Lefkofsky, CEO of Tempus AI, Inc., sold 151,520 shares of Class A Common Stock for approximately $7.7 million on March 26, 2026, through indirect entities. Despite the sale, he maintains significant indirect holdings in the company. This transaction occurred amidst a 28% year-to-date decline in the stock's price, following a strong fourth-quarter earnings report where Tempus AI surpassed analyst expectations and announced an expanded collaboration with Merck.
Tempus AI (TEM) CEO-linked entities sell 166K shares under 10b5-1 plan
Entities linked to Tempus AI (TEM) CEO Eric P. Lefkofsky sold 166,250 shares of Class A Common Stock on March 26, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were made at weighted average prices ranging from approximately $45.78 to $47.42. Despite these sales, Lefkofsky-linked entities Gray Media, LLC and Blue Media, LLC, along with other direct and indirect holdings, retain significant ownership in Tempus AI.
Tempus AI (NASDAQ: TEM) insiders and affiliates report Class A stock sales
Tempus AI, Inc. (NASDAQ: TEM) has reported proposed and recent sales of Class A Common stock via a Form 144 filing. The filing indicates transactions by insiders and affiliates, including Eric Lefkofsky and entities like Blue Media, LLC and Gray Media, LLC, with specific share counts and dates provided for both past sales and intended dispositions. The document also details the acquisition and payment history for some of the securities being sold.
Cathie Wood Chooses Medical AI Over Mark Zuckerberg: Ark Loads Up On TEM Stock, Dumps Meta Shares
Cathie Wood's Ark Invest made significant trades, including increasing its holdings in Tempus AI Inc (TEM) due to its collaboration with Daiichi Sankyo for AI-driven biomarker discovery in oncology. Concurrently, Ark divested Meta Platforms Inc (META) shares amid Meta's legal challenges and layoffs. The firm also sold shares in Archer Aviation Inc (ACHR) and Block Inc (XYZ), while making other strategic adjustments in various companies.
Tempus AI (Nasdaq:TEM) - Stock Analysis
This article provides a stock analysis of Tempus AI (Nasdaq:TEM), a healthcare technology company specializing in genomics and data platforms. It highlights the company's current valuation, future growth prospects, past performance, financial health, and dividend policy, along with recent news and analyst narratives. The analysis suggests Tempus AI is trading significantly below its estimated fair value but is currently unprofitable, despite strong projected revenue growth.
Tempus AI, Inc. Class A Trade Ideas — BX:TEM
This article compiles various trade ideas and analyses for Tempus AI, Inc. (TEM). Several contributors offer insights ranging from technical analysis to fundamental assessments, with most presenting a "Buy" rating based on the company's strong growth potential in the AI healthcare market, strategic partnerships, and financial performance. The article also provides a detailed strategy for utilizing call options and outlines associated risks and risk management techniques.
Tempus AI CFO Sells Over 11K Shares
Rogers James William, the Chief Financial Officer of Tempus AI (TEM), sold 11,414 shares of Class A Common Stock on March 2, 2026. The transaction totaled $578,575 at a price of $50.69 per share and was conducted under a Rule 10b5-1 trading plan. Following this sale, the CFO still directly owns 127,248 shares of the company.
Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
Two lawsuits have been filed against Tempus AI, Inc. in the U.S. District Court for the Northern District of Illinois, alleging violations of the Illinois Genetic Information Privacy Act. The lawsuits stem from Tempus AI's acquisition of Ambry Genetics and the subsequent integration of its genetics data into Tempus's predictive models. This raises critical questions about proper consent for data use, especially concerning the concept of "de-identified" versus "de-identifiable" germline DNA data in the rapidly advancing field of AI and genomics.
Tempus AI (TEM) Is Down 6.9% After Raising 2026 Outlook And Filing ESOP Shelf Offering
Tempus AI (TEM) saw its stock drop by 6.9% despite reporting stronger 2025 results, raising its 2026 revenue guidance to approximately US$1.59 billion, and launching a new oncology algorithm. The company also filed a US$343.38 million Class A common stock shelf registration related to an ESOP offering. While these updates signal rapid top-line growth and narrowing losses, investors are balancing the company's significant investment in AI-driven diagnostics against ongoing risks like reimbursement and competition.
Director David R. Epstein sells Tempus AI (TEM) shares under 10b5-1 plan
Tempus AI director David R. Epstein sold 250 shares of Class A Common Stock at $50.69 per share on March 2, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in August 2024. Following this transaction, Epstein directly holds 25,801 shares. This insider trade was reported via a SEC Form 4 filing, indicating a neutral filing impact but negative sentiment.
